<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6426">
  <stage>Registered</stage>
  <submitdate>1/12/2016</submitdate>
  <approvaldate>1/12/2016</approvaldate>
  <nctid>NCT02985879</nctid>
  <trial_identification>
    <studytitle>A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-001635-12</secondaryid>
    <secondaryid>M15-562</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Progressive Supranuclear Palsy</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Neurodegenerative diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABBV-8E12
Treatment: drugs - Placebo

Experimental: Group 1 - Dose 1 ABBV-8E12

Experimental: Group 2 - Dose 2 ABBV-8E12

Placebo Comparator: Group 3 - Placebo for ABBV-8E12


Treatment: drugs: ABBV-8E12
ABBV-8E12 (20 mg/mL) solution for IV infusion

Treatment: drugs: Placebo
placebo solution for IV infusion

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in Progressive Supranuclear Palsy Rating Scale (PSP-RS) Total Score from Baseline to Week 52 - The PSP-RS is a 28-item scale comprising 6 domains (daily activities, mentation, bulbar, ocular motor, limb motor, and gait/midline).</outcome>
      <timepoint>52 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Adverse Events</outcome>
      <timepoint>52 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed serum concentration (Cmax) for ABBV-8E12</outcome>
      <timepoint>16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Cmax (Tmax) for ABBV-8E12</outcome>
      <timepoint>16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration time curve (AUC) for ABBV-8E12</outcome>
      <timepoint>16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum concentration at the end of a dose interval (Ctrough) for ABBV-8E12</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in PSP-RS Total Score from Baseline to Each Observation - The PSP-RS is a 28-item scale comprising 6 domains (daily activities, mentation, bulbar, ocular motor, limb motor, and gait/midline).</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Schwab and England Activities of Daily Living Scale (SEADL) - The SEADL assesses the subject's ability to perform daily activities.</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) - The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease.</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Clinical Global Impression of Severity (CGI-S) - The CGI-S is a clinician's rating of disease severity.</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Clinical Global Impression of Change (CGI-C) - The CGI-C is a clinician's rating of improvement in disease severity.</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Progressive Supranuclear Palsy Quality of Life (PSP-QoL) Subscale Scores and Visual Analog Scale (VAS) - The PSP-QoL is a validated patient-reported outcome measure to assess quality of life of patients with PSP.</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female subject with age 40 years or greater at the time of signed consent.

          -  Meets the criteria for possible or probable progressive supranuclear palsy
             (Steele-Richardson-Olszewski Syndrome).

          -  Presence of PSP symptoms for less than 5 years.

          -  Subject is able to walk 5 steps with minimal assistance (stabilization of one arm or
             use of cane/walker).

          -  Subject has an identified, reliable, study partner (e.g., caregiver, family member,
             social worker, or friend).</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects who weigh less than 44 kg (97 lbs) at screening.

          -  MMSE score less than 15 at screening.

          -  Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI).

          -  Subject resides at a skilled nursing or dementia care facility, or admission to such a
             facility is planned during the study period.

          -  Evidence of any clinically significant neurological disorder other than PSP.

          -  The subject has a history of or currently has schizophrenia, schizoaffective disorder
             or bipolar disorder according to DSM-V or ICD-10 criteria.

          -  Subject has had a significant illness or infection requiring medical intervention in
             the past 30 days.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>16/12/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>3/09/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Alfred Hospital /ID# 153158 - Melbourne</hospital>
    <hospital>Neurodegenerative Disorders Research Pty Ltd /ID# 153770 - Perth</hospital>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6005 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Galgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tsa40031</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pozzilli (Isernia)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Terni</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Venezia Lido</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess efficacy, safety, tolerability, and pharmacokinetics
      of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02985879</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>AbbVie Inc</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>AbbVie_Call Center</name>
      <address />
      <phone>847.283.8955</phone>
      <fax />
      <email>abbvieclinicaltrials@abbvie.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>